Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.

Humans Antibodies, Bispecific / therapeutic use Multiple Myeloma / therapy B-Cell Maturation Antigen Immunotherapy Receptors, G-Protein-Coupled / therapeutic use
BCMA Bispecific antibody FcRH5 GPRC5D Multiple myeloma

Journal

Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937

Informations de publication

Date de publication:
03 08 2023
Historique:
received: 20 06 2023
accepted: 26 07 2023
medline: 7 8 2023
pubmed: 4 8 2023
entrez: 3 8 2023
Statut: epublish

Résumé

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.

Identifiants

DOI: 10.1186/s13045-023-01489-3 PMID: 37537597 PMC: PMC10401827
pubmed: 37537597
doi: 10.1186/s13045-023-01489-3
pii: 10.1186/s13045-023-01489-3
pmc: PMC10401827
doi:

Substances chimiques

Antibodies, Bispecific 0
B-Cell Maturation Antigen 0
GPRC5D protein, human 0
Receptors, G-Protein-Coupled 0

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

92

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Moreau P, Garfall AL, Bhutani M, Oriol A, Nooka AK, Martin TG, Rosiñol L, Mateos M-V, Bahlis NJ, Popat R, Besemer B, Martinez-Lopez J, Krishnan AY, Delforge M, Trancucci D, Verona R, Stephenson T, Chastain K, Sidana S. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8011–8011.
doi: 10.1200/JCO.2023.41.16_suppl.8011
Shekarkhand T, Patel D, Tan CRC, Hultcrantz M, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Korde N, Maclachlan K, Landau HJ, Scordo M, Chung DJ, Shah GL, Lahoud OB, Giralt S, Usmani SZ. Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies. J Clin Oncol. 2023;41(16_suppl):8049–8049.
doi: 10.1200/JCO.2023.41.16_suppl.8049
Hungria VT, Bhutani D, Landgren O, Vieyra D, Guo Y, Verona R, Miao X, Qi M, Watkins L, Shah P, Chastain K, Qi M, Quach H. MajesTEC-9: a randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;41(16_suppl):8067–8067.
doi: 10.1200/JCO.2023.41.16_suppl.TPS8067
Tomasson MH, Arnulf B, Bahlis NJ, Prince HM, Niesvizky R, Rodríguez-Otero P, Martinez-Lopez J, Koehne G, Jethava Y, Gabayan AE, Stevens DA, Nooka AK, Raje NS, Iida S, Leip E, Conte U, Czibere AG, Viqueira A, Lesokhin AM. Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study. J Clin Oncol. 2023;41(16_suppl):8039–8039.
doi: 10.1200/JCO.2023.41.16_suppl.8039
Yeh S-P, Huang JSY, Byun JM, DiRienzo C, Viqueira A. MagnetisMM-6: an open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM). J Clin Oncol. 2023;41(16_suppl):TPS065-TPS8065.
Grosicki S, Kim K, Negre E, Vandendries E. MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. J Clin Oncol. 2023;41(16_suppl):TPS8066–TPS8066.
doi: 10.1200/JCO.2023.41.16_suppl.TPS8065
Bumma N, Richter JR, Dhodapkar MV, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Maly JJ, Ye JC, Wu KL, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Rodriguez-Lorenc K, Kroog GS, Houvras YJ, Jagannath S. LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;41(16_suppl):8006–8006.
doi: 10.1200/JCO.2023.41.16_suppl.8006
Qiu L, Wei Y, Jin J, Li X, Liu X, Yin S, Qi J. Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;41(16_suppl):8038–8038.
doi: 10.1200/JCO.2023.41.16_suppl.8038
Xia J, Li Z, Xu K. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting. J Hematol Oncol. 2023;16(1):60.
doi: 10.1186/s13045-023-01461-1 pubmed: 37277826 pmcid: 10240779
Touzeau C, Minnema MC, van de Donk NWCJ, Rodríguez-Otero P, Mateos M-V, Rasche L, Ye JC, Vishwamitra D, Ma X, Qin X, Campagna M, Masterson TJ, Hilder B, Tolbert JA, Renaud T, Goldberg J, Heuck C, Chari A. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16):8036–8036.
Morillo D, Gatt ME, Sebag M, Kim K, Min C-K, Oriol A, Ocio EM, Yoon S-S, Mateos M-V, Chu M, Rodríguez-Otero P, Avivi I, Guo Y, Krevvata M, Peterson MR, Beelen MJ, Vanak J, Banerjee A, Magen H. First results from the Redirectt-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8002–8002.
doi: 10.1200/JCO.2023.41.16_suppl.8002
Weisel K, Mateos M-V, Goldschmidt H, Martin TG, Morillo D, Reece DE, Rodríguez-Otero P, Bhutani M, D’Souza A, Oriol A, Rosiñol L, Bahlis NJ, Bakshi K, Kang L, Vandenberk L, Smit M-AD, Wäsch R, van de Donk NWCJ, Chari A. Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated TRIMM-2 results. J Clin Oncol. 2023;41(16_suppl):8003–8003.
doi: 10.1200/JCO.2023.41.16_suppl.8003
Bachier CR, Cavo M, Corradini P, Delforge M, Janowski W, Lesokhin AM, Mina R, Paris L, Rosiñol L, Quach H, Goodman GR, Nakamura R, Samineni D, Shah V, Fritsch EW, Berdeja JG. CAMMA 2: a phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent. J Clin Oncol. 2023;41(16_suppl):TPS8064–TPS8064.
doi: 10.1200/JCO.2023.41.16_suppl.TPS8064

Auteurs

Juanjuan Zhao (J)

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.

Quan Ren (Q)

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.

Xinyuan Liu (X)

Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, Henan, China.

Xiangqian Guo (X)

Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, Henan, China.

Yongping Song (Y)

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China. songyp@zzu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Bispecific antibodies targeting BCMA, GPRC5D,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps bispécifiques › Bispecific antibodies targeting BCMA, GPRC5D,...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Bispecific antibodies targeting BCMA, GPRC5D,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux cytokines › Récepteurs aux facteurs de nécrose tumorale › Antigène de maturation des cellules B › Bispecific antibodies targeting BCMA, GPRC5D,...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Bispecific antibodies targeting BCMA, GPRC5D,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Bispecific antibodies targeting BCMA, GPRC5D,...